1. Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers
- Author
-
Raquel Pérez-Robles, Jesús Hermosilla, Natalia Navas, Susana Clemente-Bautista, Inés Jiménez-Lozano, Maria Josep Cabañas-Poy, Julio Ruiz-Travé, María Amparo Hernández-García, Jose Cabeza, Antonio Salmerón-García, Institut Català de la Salut, [Pérez-Robles R] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. Department of Analytical Chemistry, Science Faculty, University of Granada, Granada, Spain. Fundación para la Investigación Biosanitaria de Andalucía Oriental-Alejandro Otero, Granada, Spain. [Hermosilla J, Navas N] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. Department of Analytical Chemistry, Science Faculty, University of Granada, Granada, Spain. [Clemente-Bautista S, Jiménez-Lozano I, Cabañas-Poy MJ] Servei de Farmàcia, Vall d′Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Short Bowel Syndrome ,Clinical Biochemistry ,enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::síndromes de malabsorción::síndrome del intestino corto [ENFERMEDADES] ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Pharmaceutical Science ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Analytical Chemistry ,Gastrointestinal Agents ,Drug Discovery ,Glucagon-Like Peptide 2 ,Humans ,acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos gastrointestinales [COMPUESTOS QUÍMICOS Y DROGAS] ,Spectroscopy ,Medicaments - Estabilitat ,Medicaments gastrointestinals ,Teduglutide ,Long-term stability study ,Investigative Techniques::Technology, Pharmaceutical::Drug Stability [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Intestins - Malalties - Tractament ,Revestive® ,Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Gastrointestinal Agents [CHEMICALS AND DRUGS] ,Hospital condition ,Peptides ,técnicas de investigación::tecnología farmacéutica::estabilidad de medicamentos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Plastics ,Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Malabsorption Syndromes::Short Bowel Syndrome [DISEASES] - Abstract
Hospital condition; Long-term stability study; Teduglutide Condició hospitalària; Estudi d'estabilitat a llarg termini; Teduglutida Condición hospitalaria; Estudio de estabilidad a largo plazo; Teduglutida Teduglutide, the active ingredient of the medicine Revestive® (5 mg), is a recombinant therapeutic peptide that mimics the effects of the endogenous glucagon-like peptide 2 (GLP-2). It stimulates intestinal growth, adaptation and function in patients with Short Bowel Syndrome who are dependent on parenteral nutrition. The Summary of Product Characteristics recommends immediate use of the reconstituted solutions and the discarding of any subsequent surplus. This study aims to carry out a long-term stability study that reproduces hospital conditions of use which provide sound evidence regarding the use of teduglutide surplus beyond the Summary Product Characteristics recommendations. We conducted a stability study of teduglutide solutions prepared from a 5 mg vial of Revestive®. Some of the solutions were stored in their original vial after reconstitution, while others were repackaged in plastic syringes to evaluate their physicochemical stability over time. For this purpose, we applied a set of previously validated analytical methodologies to evaluate the main critical quality attributes of teduglutide, i.e., primary (including post-tralational modifications), secondary and tertiary structures, aggregates, particulate, concentration and pH. The results indicate that the solutions maintain high physicochemical stability over time, regardless of the storage temperature (4ºC or −20ºC) or the storage container (vials or syringes). This research provides new data on the stability of Revestive® that will be of great value to hospital pharmacists. This comprehensive assessment of the physicochemical long-term stability of TGT has demonstrated that under the storage conditions and over the period studied here, the medicine maintains its quality, efficacy and safety profiles. Fundación Andaluza de Farmacia Hospitalaria (Spain); Hospital Paediatrics Pharmacy Unit of the Hospital Vall d′ Hebron (Barcelona, Spain); Junta de Andalucia (Spain), Universidad de Granada (Spain).
- Published
- 2022